Cryoablation for Secondary Renal Cell Carcinoma After Surgical Nephrectomy
Autor: | Keisuke Ishimatsu, Yoshiki Asayama, Kousei Ishigami, Yukihisa Takayama, Yuichiro Kubo, Akihiro Nishie, Yasuhiro Ushijima |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Urology Rate control Renal function Cryoablation Single Center medicine.disease Nephrectomy 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma Medicine Radiology Nuclear Medicine and imaging Stage (cooking) Cardiology and Cardiovascular Medicine business Survival rate |
Zdroj: | CardioVascular and Interventional Radiology. 44:414-420 |
ISSN: | 1432-086X 0174-1551 |
Popis: | To retrospectively evaluate the clinical outcomes of cryoablation for secondary renal cell carcinoma for patients with a history of nephrectomy for initial renal cell carcinoma. Thirty patients with 40 renal tumors who had undergone a nephrectomy for initial renal cell carcinoma and cryoablation for renal cell carcinoma as a secondary treatment during the period from April 2014 to December 2018 at a single center institution were enrolled. The patients' overall survival, local control, relapse-free survival, change of renal function, and complications were evaluated. The clinical factors of relapse-free survival were also evaluated. The 5 year overall survival rate was 94.5%, the 5 year local control rate was 89.3%, and the 5 year relapse-free survival rate (RFSR) was 56.3%. There was an average reduction in renal function of 8.5% after 1 year, and > grade 3 complications occurred in only one case. The RFSR in the patients whose initial stage was T3 was 0%, significantly lower than the 70.4% RFSR in the patients whose initial stage was T1 or T2. Cryoablation for secondary renal cell carcinoma after nephrectomy was safe and provided good local control with preserved renal function. However, the indications for cryoablation should be carefully considered for patients with T3-stage initial renal cell carcinoma, because of the high risk of relapse. III |
Databáze: | OpenAIRE |
Externí odkaz: |